Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 5 of 5
SESSION INTRODUCTION
Ethel D. Weld
The Johns Hopkins University, Baltimore, MD, USA
from CROI 2020 on March 11, 2020 1:30 PM-2:30 PM
CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION   (ABSTRACT 466)
Susan Ford
GlaxoSmithKline, RTP, NC, USA
from CROI 2020 on March 11, 2020 1:30 PM-2:30 PM
MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV INFECTION   (ABSTRACT 468)
Randolph P Matthews
Merck Research Laboratories, North Wales, PA, USA
from CROI 2020 on March 11, 2020 1:30 PM-2:30 PM
DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207   (ABSTRACT 469)
Eric Daar
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
from CROI 2020 on March 11, 2020 1:30 PM-2:30 PM
ANTIRETROVIRAL & RIFAMPICIN COTREATMENT AFFECTS DMPA EXPOSURE: DOSING IMPLICATIONS   (ABSTRACT 471)
Jose Francis
University of Cape Town, Cape Town, Western Cape, South Africa
from CROI 2020 on March 11, 2020 1:30 PM-2:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 5 of 5